Zhitong Finance App learned that on March 12, 2024, Guanhe Pharmaceutical and China Biotech Services Holdings Limited (08037) reached a strategic cooperation to jointly establish the “China Biotech Service-Guanhe Joint Laboratory” in Hong Kong. This cooperation is based on the principles of complementary advantages, common development and win-win cooperation between the two parties, and aims to promote the application and development of innovative drugs such as cell therapy technology, small molecule drugs, and ADC drugs in the biomedical field.

The joint laboratory brought together the technical resources and research forces of Shanghai and Hong Kong companies to form a strong R&D team focusing on in-depth research and commercial development of accurate detection and cell therapy technology. This cooperation will promote the further integration of Chinese medicine services with international clinical trial services to ensure compliance with national regulations and international standards.

The joint laboratory will provide CRO clinical research services for clinical trials in Hong Kong, Mainland China and international, to help Hong Kong's innovative pharmaceutical companies develop new drugs and conduct clinical trials. In addition, the joint laboratory will also provide international and specialized CRO services for the “Hong Kong Drug and Medical Device Supervision and Administration Center” and the “Greater Bay Area International Clinical Trials Institute” currently being prepared by the Hong Kong Government, promoting Hong Kong to become a medical innovation hub and helping the development of advanced diagnosis and treatment technology and pharmaceutical device research and development.

As a company listed on the Hong Kong Stock Exchange, Zhongsheng Services is committed to building an advanced biotechnology platform integrating cancer diagnosis and treatment. Its business segments, such as PHC Standard Pathology Laboratory, AMDL Asia Molecular Diagnostic Laboratory, and vCare Zhuoji Healthcare, have rich experience and high recognition in the fields of medical testing, molecular diagnosis, and health management.

Guanhe Pharmaceutical is a one-stop clinical research laboratory service solution provider established as a joint venture between Dian Diagnostics (300244.SZ) and Tiger Pharmaceuticals (3347.HK). The company strictly complies with GCP regulations, complies with international standards, and provides laboratory services related to clinical drug research for pharmaceutical companies, CRO and scientific research institutions. Its rich laboratory technology and project management experience is widely recognized in the field of drug clinical trials.

This cooperation will bring great prospects for win-win cooperation between the two companies. The two sides will further strengthen cooperation in cutting-edge biomedical research, talent development, and transformation of research results. Through joint research and development, resource sharing, and market expansion, the two sides will further enhance their technical strength and market competitiveness. At the same time, the joint laboratory is based in Hong Kong, backed by the Greater Bay Area, and radiating Southeast Asia. It will inject new vitality into the development of the biomedical industry, promote the rapid development of the entire biomedical industry, and bring more welfare to society and people.